Conmed price target raised to $145 from $128 at Piper Sandler

Piper Sandler analyst Matt O’Brien raised the firm’s price target on Conmed to $145 from $128 and keeps an Overweight rating on the shares post the Q2 beat. The analyst says the company’s end markets are healthy while the competitive AirSeal noise is a “non-issue.”